OMP-305B83

DRUG3 trials

Sponsors

OncoMed Pharmaceuticals, Inc.

Conditions

Advanced Solid Tumor MalignanciesCancer OvariesCancer PeritonealCancer, Fallopian TubeMetastatic Colorectal Cancer

Phase 1

A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors

CompletedNCT02298387

OncoMed Pharmaceuticals, Inc.Advanced Solid Tumor Malignancies

Start: 2014-12-22End: 2017-09-08Updated: 2020-08-11

A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer

CompletedNCT03030287

OncoMed Pharmaceuticals, Inc.Cancer, Fallopian Tube, Cancer Ovaries, Cancer Peritoneal

Start: 2016-12-31End: 2020-04-30Updated: 2020-09-03

A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer

TerminatedNCT03035253

OncoMed Pharmaceuticals, Inc.Metastatic Colorectal Cancer

Start: 2016-12-31End: 2018-12-31Updated: 2020-08-11

Related Papers

A phase Ib study of navicixizumab & weekly paclitaxel in heavily pre-treated platinum resistant ovarian, primary peritoneal or fallopian tube cancer

Annals of Oncology2018-10-013 citations